Multimodality treatment including surgery for primary pulmonary sarcoma: Size does matter
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
Background and Objectives: Primary pulmonary sarcoma (PPS) accounts for less than 1.1% of all pulmonary tumors. Few outcome data are reported. We evaluated outcome and prognostic factors in our series. Methods: We retrospectively reviewed all patients who underwent resection for PPS in our center from 2002 to 2018. Survival was calculated from the date of surgery until last follow-up. Impact on survival of gender, type of lung resection, completeness of resection, grade, size, and TNM staging for lung cancer and soft tissue sarcoma (STS) was assessed. Results: Thirteen patients were included. Eight (61.5%) patients received neoadjuvant treatment. Median tumor size at diagnosis was 11.5 cm (1-30 cm). Type of lung resection was wedge (n = 2, 15%), lobectomy (n = 4, 31%), intrapericardial (n = 3, 23%), and extrapleural pneumonectomies (n = 4, 31%). In-hospital mortality was 8%. Overall 5-year survival was 60%. Median disease-free survival was 17 months. Tumor size was a predictor for survival (P =.02) and recurrence (P =.05). Gender (P =.04) and type of lung resection (P =.04) were predictors of survival. T stage for STS of trunk and extremity, and TNM stage for lung cancer were predictors for recurrence (P =.03 and P =.04, respectively). Conclusion: Surgical resection within a multimodality therapy concept in highly selected patients can offer good long-term outcome.
Details
Original language | English |
---|---|
Pages (from-to) | 506-514 |
Number of pages | 9 |
Journal | Journal of surgical oncology |
Volume | 122 |
Issue number | 3 |
Publication status | Published - 1 Sept 2020 |
Peer-reviewed | Yes |
Externally published | Yes |
External IDs
PubMed | 32410271 |
---|
Keywords
Sustainable Development Goals
Keywords
- induction, lung sarcoma, multimodality treatment, primary pulmonary sarcoma, surgery